Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodney Sinclair

Showing results (201-210 of 256) with videos related to

Pageof 26
Sort By:
International Journal of Dermatology|July 11, 2024
Isotretinoin as a promising option in the treatment of facial papules of frontal fibrosing alopeciaAmir Mohammad Beyzaee, Mahsa Babaei, Bahare Ghoreishi, et al.
American Journal of Clinical Dermatology|March 1, 2023
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)Ohsang Kwon, Maryanne M Senna, Rodney Sinclair, et al.
Dermatologic Therapy|April 12, 2019
Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymesAseem Sharma, Andy Goren, Rachita Dhurat, et al.
American Journal of Clinical Dermatology|April 11, 2025
Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of TreatmentBrett King, Arash Mostaghimi, Yutaka Shimomura, et al.
Dermatology and Therapy|May 22, 2026
Description of the Tranquillo Phase 3 Clinical Trial Designs/Study Protocols to Assess Ritlecitinib in Adults and Adolescents with Nonsegmental VitiligoTatjana Lukic, Pranab Ghosh, Lynne Napatalung, et al.
The British Journal of Dermatology|September 14, 2023
When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trialsBrett King, Jerry Shapiro, Manabu Ohyama, et al.
Medical Hypotheses|December 14, 2020
Androgenetic alopecia may be associated with weaker COVID-19 T-cell immune response: An insight into a potential COVID-19 vaccine boosterAndy Goren, Flavio Adsuara Cadegiani, Carlos Gustavo Wambier, et al.
Dermatology and Therapy|October 14, 2025
Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia AreataBrett King, Amy McMichael, Rodney Sinclair, et al.
The EMBO Journal|February 22, 2008
Perturbed desmosomal cadherin expression in grainy head-like 1-null miceTomasz Wilanowski, Jacinta Caddy, Stephen B Ting, et al.
The British Journal of Dermatology|February 10, 2023
Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trialsBrett King, Arash Mostaghimi, Yutaka Shimomura, et al.
Pageof 26

Showing results (201-210 of 256) with videos related to

Sort By:
Pageof 26
International Journal of Dermatology|July 11, 2024
Isotretinoin as a promising option in the treatment of facial papules of frontal fibrosing alopeciaAmir Mohammad Beyzaee, Mahsa Babaei, Bahare Ghoreishi, et al.
American Journal of Clinical Dermatology|March 1, 2023
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)Ohsang Kwon, Maryanne M Senna, Rodney Sinclair, et al.
Dermatologic Therapy|April 12, 2019
Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymesAseem Sharma, Andy Goren, Rachita Dhurat, et al.
American Journal of Clinical Dermatology|April 11, 2025
Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of TreatmentBrett King, Arash Mostaghimi, Yutaka Shimomura, et al.
Dermatology and Therapy|May 22, 2026
Description of the Tranquillo Phase 3 Clinical Trial Designs/Study Protocols to Assess Ritlecitinib in Adults and Adolescents with Nonsegmental VitiligoTatjana Lukic, Pranab Ghosh, Lynne Napatalung, et al.
The British Journal of Dermatology|September 14, 2023
When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trialsBrett King, Jerry Shapiro, Manabu Ohyama, et al.
Medical Hypotheses|December 14, 2020
Androgenetic alopecia may be associated with weaker COVID-19 T-cell immune response: An insight into a potential COVID-19 vaccine boosterAndy Goren, Flavio Adsuara Cadegiani, Carlos Gustavo Wambier, et al.
Dermatology and Therapy|October 14, 2025
Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia AreataBrett King, Amy McMichael, Rodney Sinclair, et al.
The EMBO Journal|February 22, 2008
Perturbed desmosomal cadherin expression in grainy head-like 1-null miceTomasz Wilanowski, Jacinta Caddy, Stephen B Ting, et al.
The British Journal of Dermatology|February 10, 2023
Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trialsBrett King, Arash Mostaghimi, Yutaka Shimomura, et al.
Pageof 26